Free Trial

Dynavax Technologies (DVAX) Competitors

Dynavax Technologies logo
$10.80 +0.02 (+0.14%)
As of 03:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DVAX vs. ACAD, ALKS, BOLT, CORT, GILD, LGND, MRK, FOLD, BCRX, and CLDX

Should you be buying Dynavax Technologies stock or one of its competitors? The main competitors of Dynavax Technologies include ACADIA Pharmaceuticals (ACAD), Alkermes (ALKS), Bolt Biotherapeutics (BOLT), Corcept Therapeutics (CORT), Gilead Sciences (GILD), Ligand Pharmaceuticals (LGND), Merck & Co., Inc. (MRK), Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), and Celldex Therapeutics (CLDX). These companies are all part of the "medical" sector.

Dynavax Technologies vs. Its Competitors

Dynavax Technologies (NASDAQ:DVAX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Dynavax Technologies presently has a consensus target price of $24.33, indicating a potential upside of 125.20%. ACADIA Pharmaceuticals has a consensus target price of $28.88, indicating a potential upside of 14.67%. Given Dynavax Technologies' higher possible upside, equities analysts plainly believe Dynavax Technologies is more favorable than ACADIA Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dynavax Technologies
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50
ACADIA Pharmaceuticals
1 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.61

In the previous week, ACADIA Pharmaceuticals had 11 more articles in the media than Dynavax Technologies. MarketBeat recorded 19 mentions for ACADIA Pharmaceuticals and 8 mentions for Dynavax Technologies. ACADIA Pharmaceuticals' average media sentiment score of 0.82 beat Dynavax Technologies' score of 0.76 indicating that ACADIA Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dynavax Technologies
4 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
ACADIA Pharmaceuticals
7 Very Positive mention(s)
2 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

97.0% of Dynavax Technologies shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 3.0% of Dynavax Technologies shares are owned by insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has higher revenue and earnings than Dynavax Technologies. Dynavax Technologies is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dynavax Technologies$277.25M4.57$27.31M-$0.46-23.49
ACADIA Pharmaceuticals$957.80M4.44$226.45M$1.3318.93

Dynavax Technologies has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500.

ACADIA Pharmaceuticals has a net margin of 21.80% compared to Dynavax Technologies' net margin of -16.67%. ACADIA Pharmaceuticals' return on equity of 14.69% beat Dynavax Technologies' return on equity.

Company Net Margins Return on Equity Return on Assets
Dynavax Technologies-16.67% 5.10% 3.00%
ACADIA Pharmaceuticals 21.80%14.69%9.41%

Summary

ACADIA Pharmaceuticals beats Dynavax Technologies on 13 of the 17 factors compared between the two stocks.

Get Dynavax Technologies News Delivered to You Automatically

Sign up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DVAX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DVAX vs. The Competition

MetricDynavax TechnologiesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.27B$3.13B$5.71B$9.79B
Dividend YieldN/A2.21%3.77%4.10%
P/E Ratio-23.4720.9230.9125.28
Price / Sales4.57232.70404.2188.50
Price / Cash68.1441.5625.2228.45
Price / Book2.389.779.536.01
Net Income$27.31M-$54.74M$3.26B$265.34M
7 Day Performance3.10%8.37%4.66%2.89%
1 Month Performance0.79%7.94%5.35%1.61%
1 Year Performance-3.53%18.27%32.14%25.61%

Dynavax Technologies Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DVAX
Dynavax Technologies
4.4801 of 5 stars
$10.81
+0.1%
$24.33
+125.2%
-3.7%$1.27B$277.25M-23.47350
ACAD
ACADIA Pharmaceuticals
3.8977 of 5 stars
$24.82
+0.9%
$28.88
+16.3%
+64.5%$4.15B$957.80M18.66510Analyst Upgrade
ALKS
Alkermes
4.7892 of 5 stars
$26.54
-0.6%
$41.08
+54.8%
+6.6%$4.41B$1.56B12.761,800Positive News
BOLT
Bolt Biotherapeutics
3.3993 of 5 stars
$5.54
-0.6%
$50.00
+803.0%
-62.9%$10.68M$7.69M-0.1790News Coverage
Earnings Report
Analyst Forecast
CORT
Corcept Therapeutics
4.7155 of 5 stars
$71.97
-0.5%
$134.50
+86.9%
+111.2%$7.62B$675.04M63.69300Positive News
GILD
Gilead Sciences
4.8474 of 5 stars
$120.47
+0.9%
$114.82
-4.7%
+60.4%$148.16B$28.75B24.0017,600Positive News
Analyst Revision
LGND
Ligand Pharmaceuticals
3.8321 of 5 stars
$147.01
-2.0%
$157.00
+6.8%
+47.8%$2.90B$167.13M-36.7580Short Interest ↓
Gap Down
High Trading Volume
MRK
Merck & Co., Inc.
4.9972 of 5 stars
$80.09
-0.7%
$107.44
+34.1%
-25.8%$201.55B$64.17B12.3475,000Positive News
Analyst Revision
FOLD
Amicus Therapeutics
4.2312 of 5 stars
$6.66
-1.5%
$16.22
+143.6%
-35.5%$2.08B$528.29M-55.50480Positive News
BCRX
BioCryst Pharmaceuticals
4.2552 of 5 stars
$8.20
-1.2%
$16.70
+103.7%
+9.6%$1.74B$450.71M-45.55530Insider Trade
CLDX
Celldex Therapeutics
1.5879 of 5 stars
$20.01
-3.1%
$50.11
+150.4%
-25.4%$1.37B$7.02M-6.65150

Related Companies and Tools


This page (NASDAQ:DVAX) was last updated on 8/18/2025 by MarketBeat.com Staff
From Our Partners